Personalized heparin blood-thinner testing for HIT patients
Treatments studied
Part of Blood & lymphatic clinical trials.
This study looks at whether genetic and blood test information can help manage heparin-induced thrombocytopenia (HIT), a condition where blood platelets drop after heparin use. If you’ve been evaluated for HIT and received certain heparin medicines, your results may help researchers choose safer, more personalized care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years old or older
- Be able to understand the study and sign consent
- You’ve already had blood testing for HIT using a heparin/PF4 antibody test (with or without another test called SRA)
- You received unfractionated heparin or a low-molecular-weight heparin like enoxaparin, dalteparin, or tinzaparin before the HIT antibody/SRA test
- You must not be pregnant and must be able to participate safely
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how blood cells clump together in patients who may have heparin-induced thrombocytopenia (HIT), a condition where heparin causes a drop in platelets. It aims to better understand the disease and improve diagnosis.
This study tests a blood-derived medicine (antithrombin) to help people who do not respond well to the blood thinner heparin during heart surgery. It aims to make surgery safer by improving blood thinning.
This study looks at how well a blood test (PTT) monitors the blood thinner heparin in hospital patients. If you are getting heparin through an IV, this research may help improve how your treatment is managed.
This study looks at different ways to help blood clot in people with hemophilia who have developed inhibitors (proteins that stop standard clotting treatments from working). It may help doctors choose the safest, most effective clotting approach for these situations.
This study looks at specific immune blood tests to understand why some people with immune thrombocytopenia (ITP) also develop blood clots. Results may help doctors better assess clot risk in ITP and sort out which antibodies are involved.
This trial checks whether blood samples taken from a central line using either a syringe flush or a vacuum tube give the same heparin activity results as blood from a vein in the arm. It is designed for patients in the ICU who are on a steady heparin drip.
Hear when a new Heparin-induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.